Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen novartis Collaboration — Collaboration Revenue (legacy) ($M) ($M)
Form 10-K Collaborations Note (XBRL)
Latest, Q4 2018
0
Period ended Dec 31, 2018
Change on a year earlier
–
0 in Q4 2017
History
5 quarters
Since Q3 2017
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Novartis Collaboration — Collaboration Revenue (legacy) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | 0 | – | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 147 | +145.0% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jun 30, 2018 | 148 | – | Form 10-Q (filed 2018-07-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 0 | – | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 60 | – | Form 10-Q (filed 2018-10-31) ↗ |
Cite this data
StockData. (2026). Amgen Novartis Collaboration — Collaboration Revenue (legacy) ($M) ($M), quarterly Q3 2017–Q4 2018 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/collab_novartis_rev
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.